ישראל - עברית - Ministry of Health

medison pharma ltd - dimethyl fumarate - dimethyl fumarate 240 mg - dimetyl fumarate

ישראל - עברית - Ministry of Health

medison pharma ltd - dimethyl fumarate - dimethyl fumarate 240 mg - dimetyl fumarate

ישראל - עברית - Ministry of Health

medison pharma ltd - dimethyl fumarate - dimethyl fumarate 240 mg - dimetyl fumarate

ישראל - עברית - Ministry of Health

medison pharma ltd - peginterferon beta 1a - תמיסה להזרקה - peginterferon beta 1a 125 mcg / 0.5 ml - peginterferon beta-1a

ישראל - עברית - Ministry of Health

medison pharma ltd - peginterferon beta 1a - תמיסה להזרקה - peginterferon beta 1a 63 mcg / 0.5 ml - peginterferon beta-1a

ישראל - עברית - Ministry of Health

medison pharma ltd - peginterferon beta 1a - תמיסה להזרקה - peginterferon beta 1a 94 mcg / 0.5 ml - peginterferon beta-1a

ישראל - עברית - Ministry of Health

medison pharma ltd - diroximel fumarate - diroximel fumarate 231 mg

ישראל - עברית - Ministry of Health

medison pharma ltd - interferon beta 1a 30 mcg/vial - powder for solution for injection - interferon beta-1a - avonex is indicated for the treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and to decrease the frequency of clinical exacerbations. avonex is also indicated for the treatment of patients who have experienced a single demyelinating event with an active inflammatory process if it is severe enough to warrant treatment with intravenous corticosteroids if alternative diagnosis have been excluded, including the prescence of mri abnormalities characteristic of ms and if they are determined to be at high risk of developing clinically definite multiple sclerosis. safety and efficacy in patients with chronic progressive multiple sclerosis has not been evaluated.

ישראל - עברית - Ministry of Health

medison pharma ltd - natalizumab - תרכיז להכנת תמיסה לאינפוזיה - natalizumab 300 mg / 15 ml - natalizumab - natalizumab - tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis . to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. the safety and efficacy of tysabri beyond two years are unknown. because tysabri increases the risk of progressive multifocal leukoencephalopathy (pml), an opportunistic viral infection of the brain that usually leads to death or severe disability. tysabri is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate multiple sclerosis therapies. safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.

ישראל - עברית - Ministry of Health

sanofi - aventis israel ltd - coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - coagulation factor viii 1000 iu - coagulation factor vii